Aurora kinase inhibitor patents and agents in clinical testing: An update (2011-2013)

Chun Hei Antonio Cheung, Sailu Sarvagalla, Jane Ying Chieh Lee, Yi Chun Huang, Mohane Selvaraj Coumar

研究成果: Review article同行評審

43 引文 斯高帕斯(Scopus)

摘要

Introduction: Aurora kinase A, B and C, members of serine/threonine kinase family, are key regulators of mitosis. As Aurora kinases are overexpressed in many of the human cancers, small-molecule inhibitors of Aurora kinase have emerged as a possible treatment option for cancer. Areas covered: In 2009 and 2011, the literature pertaining to Aurora kinase inhibitors and their patents was reviewed. Here, the aim is to update the information for Aurora kinase inhibitors in clinical trials and the patents filed between the years 2011 and 2013. Pubmed, Scopus®, Scifinder®, USPTO, EPO and www.clinicaltrials.gov databases were used for searching the literature and patents for Aurora kinase inhibitors. Expert opinion: Even though both Aurora sub-type selective as well as pan-selective inhibitors show preclinical and clinical efficacy, so far no Aurora kinase inhibitor has been approved for clinical use. Particularly, dose-limiting toxicity (neutropenia) is a key issue that needs to be addressed. Preliminary evidence suggests that the use of selective Aurora A inhibitors could avoid Aurora B-mediated neutropenia in clinical settings. Also, use of adjunctive agents such as granulocyte stimulating factor to overcome neutropenia associated with Aurora B inhibition could be an answer to overcome the toxicity and bring Aurora inhibitors to market in the future.

原文English
頁(從 - 到)1021-1038
頁數18
期刊Expert Opinion on Therapeutic Patents
24
發行號9
DOIs
出版狀態Published - 2014 九月

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

指紋 深入研究「Aurora kinase inhibitor patents and agents in clinical testing: An update (2011-2013)」主題。共同形成了獨特的指紋。

引用此